Join
Live feed
·
PRReleasevia Quantisnow
Immunic Inc. logo

Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the CMSC Annual Meeting 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis

ByQuantisnow·Wall Street's wire, on your screen.
IMUX· Immunic Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track IMUX (Immunic Inc.) and more on Quantisnow.